TY - JOUR
T1 - Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome
AU - The Tourette Syndrome Association International Consortium for Genetics (TSAICG)
AU - The Gilles de la Tourette Syndrome GWAS Replication Initiative (GGRI)
AU - The Gilles de la Tourette Syndrome GWAS Replication Initiative (GGRI)
AU - Huang, Alden Y.
AU - Yu, Dongmei
AU - Davis, Lea K.
AU - Sul, Jae Hoon
AU - Tsetsos, Fotis
AU - Ramensky, Vasily
AU - Zelaya, Ivette
AU - Ramos, Eliana Marisa
AU - Osiecki, Lisa
AU - Chen, Jason A.
AU - McGrath, Lauren M.
AU - Illmann, Cornelia
AU - Sandor, Paul
AU - Barr, Cathy L.
AU - Grados, Marco
AU - Singer, Harvey S.
AU - Nöthen, Markus M.
AU - Hebebrand, Johannes
AU - King, Robert A.
AU - Dion, Yves
AU - Rouleau, Guy
AU - Budman, Cathy L.
AU - Depienne, Christel
AU - Worbe, Yulia
AU - Hartmann, Andreas
AU - Müller-Vahl, Kirsten R.
AU - Stuhrmann, Manfred
AU - Aschauer, Harald
AU - Stamenkovic, Mara
AU - Schloegelhofer, Monika
AU - Konstantinidis, Anastasios
AU - Lyon, Gholson J.
AU - McMahon, William M.
AU - Barta, Csaba
AU - Tarnok, Zsanett
AU - Nagy, Peter
AU - Batterson, James R.
AU - Rizzo, Renata
AU - Cath, Danielle C.
AU - Wolanczyk, Tomasz
AU - Berlin, Cheston
AU - Malaty, Irene A.
AU - Okun, Michael S.
AU - Woods, Douglas W.
AU - Rees, Elliott
AU - Pato, Carlos N.
AU - Pato, Michele T.
AU - Knowles, James A.
AU - Posthuma, Danielle
AU - Pauls, David L.
N1 - Funding Information:
P.S., M.G., H.S.S., R.A.K., Y.D., G.R., C.L. Budman, G.J.L., W.M.M., D.L.P, N.J.C., N.B.F., P.P., C.A.M., and J.M.S. have received research funding from the TAA. J.M.S. and C.A.M. have received travel support from the TAA and serve on the TAA Scientific Advisory Board. P.S. received unrestricted Educational Grants in support of conferences he organized from Purdue and Shire, a CME speaker fee from Purdue University, and industry-sponsored clinical trial support from Otsuka and is a member of the Data Safety Monitoring Committee at Psyadon. C.L. Budman has received funding for clinical trials from Psyadon Pharmaceuticals, Neurocrine Pharmaceuticals, Synchroneuron Pharmaceuticals, AUSPEX Pharmaceuticals, and TEVA Pharmaceuticals. She was a paid speaker for the TAA CDC program and a paid consultant for Bracket eCOA. I.A.M. has participated in research funded by the National Parkinson Foundation, TAA, Abbvie, Auspex, Biotie, Michael J. Fox Foundation, Neurocrine, Pfizer, and Teva, but has no owner interest in any pharmaceutical company. I.A.M. has been reimbursed for speaking for the National Parkinson Foundation and TAA. M.S.O. serves as a consultant for the National Parkinson Foundation and has received research grants from NIH, NPF, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the TAA, and the UF Foundation. M.S.O.’s DBS research is supported by NIH grants R01 NR014852 and R01 NS096008 . He has previously received honoraria, but in the past >60 months has received no support from industry. M.S.O. has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients, and Cambridge; is an associate editor for New England Journal of Medicine Journal Watch Neurology; and has participated in CME and educational activities on movement disorders in the last 36 months sponsored by PeerView, Prime, QuantiaMD, WebMD, Medicus, MedNet, Henry Stewart, and by Vanderbilt University. The institution and not M.S.O. receives grants from Medtronic, Abbvie, Allergan, and ANS/St. Jude, and the PI has no financial interest in these grants. D.W.W. has received royalties from Guilford Press and Oxford University Press and speaking honoraria from the TAA and serves on the TAA Medical Advisory Board. All other authors have no competing financial interests to declare.
Funding Information:
The authors thank the patients with Tourette Syndrome and their families, and all the volunteers who participated in this study. This study was supported by the US NIH Grant U01 NS040024 to D.L.P., C.A.M., and J.M.S. and the TSAICG; NIH ARRA Grant NS040024-09S1 and NIH Grants K23 MH085057 and K02 NS085048 to J.M.S.; NIH ARRA Grant NS040024-07S1 and NIH Grant NS016648 to D.L.P.; NIH Grant MH096767 to C.A.M.; NINDS Informatics Center for Neurogenetics and Neurogenomics Grant P30 NS062691 to G.C. and N.B.F.; grants from the Tourette Association of America (TAA) to P.P., D.L.P., C.A.M., and J.M.S.; and from the German Research Society to J.H.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/6/21
Y1 - 2017/6/21
N2 - Tourette syndrome (TS) is a model neuropsychiatric disorder thought to arise from abnormal development and/or maintenance of cortico-striato-thalamo-cortical circuits. TS is highly heritable, but its underlying genetic causes are still elusive, and no genome-wide significant loci have been discovered to date. We analyzed a European ancestry sample of 2,434 TS cases and 4,093 ancestry-matched controls for rare (< 1% frequency) copy-number variants (CNVs) using SNP microarray data. We observed an enrichment of global CNV burden that was prominent for large (> 1 Mb), singleton events (OR = 2.28, 95% CI [1.39–3.79], p = 1.2 × 10−3) and known, pathogenic CNVs (OR = 3.03 [1.85–5.07], p = 1.5 × 10−5). We also identified two individual, genome-wide significant loci, each conferring a substantial increase in TS risk (NRXN1 deletions, OR = 20.3, 95% CI [2.6–156.2]; CNTN6 duplications, OR = 10.1, 95% CI [2.3–45.4]). Approximately 1% of TS cases carry one of these CNVs, indicating that rare structural variation contributes significantly to the genetic architecture of TS. Tourette syndrome is highly genetic, but identifying definitive disease susceptibility genes has been challenging. Huang et al. report two genome-wide, significant, recurrent, rare copy-number variants (NRXN1 deletions and CNTN6 duplications), each conferring a substantial increase in TS risk.
AB - Tourette syndrome (TS) is a model neuropsychiatric disorder thought to arise from abnormal development and/or maintenance of cortico-striato-thalamo-cortical circuits. TS is highly heritable, but its underlying genetic causes are still elusive, and no genome-wide significant loci have been discovered to date. We analyzed a European ancestry sample of 2,434 TS cases and 4,093 ancestry-matched controls for rare (< 1% frequency) copy-number variants (CNVs) using SNP microarray data. We observed an enrichment of global CNV burden that was prominent for large (> 1 Mb), singleton events (OR = 2.28, 95% CI [1.39–3.79], p = 1.2 × 10−3) and known, pathogenic CNVs (OR = 3.03 [1.85–5.07], p = 1.5 × 10−5). We also identified two individual, genome-wide significant loci, each conferring a substantial increase in TS risk (NRXN1 deletions, OR = 20.3, 95% CI [2.6–156.2]; CNTN6 duplications, OR = 10.1, 95% CI [2.3–45.4]). Approximately 1% of TS cases carry one of these CNVs, indicating that rare structural variation contributes significantly to the genetic architecture of TS. Tourette syndrome is highly genetic, but identifying definitive disease susceptibility genes has been challenging. Huang et al. report two genome-wide, significant, recurrent, rare copy-number variants (NRXN1 deletions and CNTN6 duplications), each conferring a substantial increase in TS risk.
KW - CNTN6
KW - NRXN1
KW - Tourette Syndrome
KW - copy number variation
KW - genetics
KW - neurodevelopmental disorders
KW - structural variation
KW - tic disorders
UR - http://www.scopus.com/inward/record.url?scp=85027263762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027263762&partnerID=8YFLogxK
U2 - 10.1016/j.neuron.2017.06.010
DO - 10.1016/j.neuron.2017.06.010
M3 - Article
C2 - 28641109
AN - SCOPUS:85027263762
SN - 0896-6273
VL - 94
SP - 1101-1111.e7
JO - Neuron
JF - Neuron
IS - 6
ER -